Clinical Trials
Radium-223, Prolonging Survival in Combination with Enzalutamide at an Earlier Disease State
The world of genitourinary oncology is and should be quite enamored with radioligand therapy for men with prostate cancer. The recent regulatory approvals that followed 177Lu-PSMA-617 after the positive survival results from the VISION trial,1 and the recent radiographic progression-free survival results from the PSMAfore trial in the earlier chemotherapy-naive metastatic castration-resistant prostate cancer disease state are compelling.2 This data is recently followed with data from the SPLASH trial, where 177Lu-PNT2002 has shown a significant radiographic progression free survival benefit in the chemotherapy-naïve metastatic castration-resistant prostate cancer disease state.3 We will await to see what regulatory agencies do with the data from both the PSMAfore and SPLASH trials and whether radioligand therapy use moves earlier in the treatment paradigm.
Evan Y. Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.
Clinical Expertise
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
- Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
- Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.